^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Multiple Myeloma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Hematol Oncol
    Title:

    Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

    Excerpt:
    We here present the first report on the combination of vemurafenib and cobimetinib in a young patient with highly resistant and rapidly progressing multiple myeloma harboring the BRAF V600E mutation who achieved a rapid and sustained response to this combination therapy.
    DOI:
    10.1002/hon.2353.